Top selling respiratory drugs in 2012
| Rank | Drug | Brand | Company | Drug class | Sales $ bn |
| 1 | Fluticasone propionate/salmeterol | Seretide/Advair | GlaxoSmithKline | ICS/LABA | 8.0 |
| 2 | Tiotropium bromide | Spiriva | Boehringer Ingelheim | LAMA | 4.6 |
| 3 | Montelukast | Singulair | Merck | LTRA | 3.9 |
| 4 | Budesonide/formoterol | Symbicort | AstraZeneca | ICS/LABA | 2.8 |
| 5 | Fluticasone propionate | Flixotide/Flovent | GlaxoSmithKline | ICS | 1.2 |
| 6 | Salbutamol/ipratropium | Combivent | Boehringer Ingelheim | SABA/SAMA | 1.1 |
| 7 | Salbutamol | Ventolin | GlaxoSmithKline | SABA | 1.0 |
| 8 | Budesonide | Pulmicort | AstaZeneca | ICS | 0.87 |
| 9 | Omalizumab | Xolair | Roche | Anti-IgE | 0.75 |
| 10 | Methylprednisolone | Medron | Pfizer | Corticosteroid | 0.5 |
Data are based on reported company sales figures. ICS: inhaled corticosteroid; LABA: long-acting β2-adrenergic agonist; LAMA: long-acting muscarinic antagonist; LTRA: leukotriene receptor antagonists; SABA: short-acting β2-agonist; SAMA: short-acting muscarinic antagonist. Reproduced from [5].